The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 401–500 of 1,029
Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs
Danelius, E., Poongavanam, V., Peintner, S., Wieske, L. H. E., Erdélyi, M., & Kihlberg, J. (2020) · Chemistry – A European Journal · doi:10.1002/chem.201905599 · Cited by 125
Drugs Targeting Protein–Protein Interactions
Chène, P. (2006) · ChemMedChem · doi:10.1002/cmdc.200600004 · Cited by 130
Li, J., Cisar, J. S., Zhou, C., Vera, B., Williams, H. J., Rodríguez, A. D., Cravatt, B. F., & Romo, D. (2013) · Nature Chemistry · doi:10.1038/nchem.1653 · Cited by 145
Ligand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
“Our improved understanding of the molecular basis of human diseases has expanded the list of targets used for developing new therapeutics [1,2].”
BackgroundInhibition of RNA-binding proteins with small molecules
Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 146
Holman, A. G., Davis, P. J., Foster, J. M., Carlow, C. K. S., & Kumar, S. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-243 · Cited by 136
“There exist several purely sequence based methods of predicting druggability based on the identification of domains favorable to small molecule binding [41,42].”
Novel Insights on Thyroid-Stimulating Hormone Receptor Signal Transduction
Kleinau, G., Neumann, S., Grüters, A., Krude, H., & Biebermann, H. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1072 · Cited by 127
Graph convolution for predicting associations between miRNA and drug resistance
Huang, Y., Hu, P., Chan, K. C. C., & You, Z. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz621 · Cited by 142
Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics
Barman, P., Joshi, S., Sharma, S., Preet, S., Sharma, S., & Saini, A. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10524-3 · Cited by 116
“Small molecules target only 2–5% of the human genome but peptides are more selective for specific protein targets (Cirillo et al. 2011; Hopkins and Groom 2002; Lau and Dunn 2018; Rask-Andersen et al. 2014; Vargason et al. 2021).”
BackgroundPagano, M. A., Poletto, G., Maira, G. D., Cozza, G., Ruzzene, M., Sarno, S., Bain, J., Elliott, M., Moro, S., Zagotto, G., et al. (2006) · ChemBioChem · doi:10.1002/cbic.200600293 · Cited by 140
Two-dimensional electrophoresis of membrane proteins
Braun, R. J., Kinkl, N., Beer, M., & Ueffing, M. (2007) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1514-6 · Cited by 155
Sheridan, R. P., Maiorov, V. N., Holloway, M. K., Cornell, W. D., & Gao, Y. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100312t · Cited by 126
Learning for Personalized Medicine: A Comprehensive Review From a Deep Learning Perspective
Zhang, S., Bamakan, S. M. H., Qu, Q., & Li, S. (2019) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2018.2864254 · Cited by 125
“conducted to evaluate indications of small molecule therapeutics [73]–[75].”
BackgroundPockDrug: A Model for Predicting Pocket Druggability That Overcomes Pocket Estimation Uncertainties
Borrel, A., Regad, L., Xhaard, H., Petitjean, M., & Camproux, A.-C. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci5006004 · Cited by 118
Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor
Lebon, G., Bennett, K. A., Jazayeri, A., & Tate, C. G. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.075 · Cited by 125
Activity-based protein profiling: Recent advances in medicinal chemistry
Deng, H., Lei, Q., Wu, Y., He, Y., & Li, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112151 · Cited by 130
Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Zhou, P., Wang, C., Ren, Y., Yang, C., & Tian, F. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320150005 · Cited by 128
Zhang, P., Park, H.-J., Zhang, J., Junn, E., Andrews, R. J., Velagapudi, S. P., Abegg, D., Vishnu, K., Costales, M. G., Childs‐Disney, J. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905057117 · Cited by 129
High yield cell-free production of integral membrane proteins without refolding or detergents
Wuu, J. J., & Swartz, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.01.023 · Cited by 123
Lessons for fragment library design: analysis of output from multiple screening campaigns
Chen, I., & Hubbard, R. E. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9280-5 · Cited by 122
Ramachandran, S. S., Karp, P. H., Jiang, P., Ostedgaard, L. S., Walz, A. E., Fisher, J. T., Keshavjee, S. H., Lennox, K. A., Jacobi, A. M., Rose, S. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210906109 · Cited by 123
“Drug screening concentrated on identifying small molecules or pharmaceuticals that inhibit SIN3A, or a core subset of gene products responsible for CFTR-ΔF508 rescue, represents another therapeutic approach (51).”
BackgroundNisius, B., Sha, F., & Gohlke, H. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.12.005 · Cited by 130
“Both requirements are combined in the term “druggability”, which was initially defined by Hopkins and Groom (2002) as the ability of a protein linked to a specific disease to bind small, drug-like molecules with high affinity.”
BackgroundBiophysical characterization of membrane proteins in nanodiscs
Inagaki, S., Ghirlando, R., & Grisshammer, R. (2012) · Methods · doi:10.1016/j.ymeth.2012.11.006 · Cited by 120
“In particular, G protein-coupled receptors (GPCRs) have intensively been targeted for therapeutic purposes [3, 4].”
BackgroundPardo, L., Deupi, X., Dölker, N., López‐Rodríguez, M. L., & Campillo, M. (2007) · ChemBioChem · doi:10.1002/cbic.200600429 · Cited by 121
Innovative approaches to bipolar disorder and its treatment
Harrison, P. J., Cipriani, A., Harmer, C. J., Nobre, A. C., Saunders, K., Goodwin, G. M., & Geddes, J. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13048 · Cited by 115
Inhibition of transcription factors with small organic molecules
Berg, T. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.07.023 · Cited by 139
Intrinsically disordered proteins and novel strategies for drug discovery
Uversky, V. N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.686489 · Cited by 115
“2 Molecular mechanisms of drugs targeting ordered proteins The majority of drug antagonists and inhibitors achieve their potency by competing with endogenous ligands or substrates at structurally defined binding sites [67,82].”
BackgroundInfluentialEpidermal differentiation: The role of proteases and their inhibitors
Zeeuwen, P. L. J. M. (2004) · European Journal of Cell Biology · doi:10.1078/0171-9335-00388 · Cited by 119
Winter, A., Higueruelo, A. P., Marsh, M., Sigurdardottir, A., Pitt, W. R., & Blundell, T. L. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000108 · Cited by 117
“Two factors conventionally define a ‘druggable’ protein target, first whether its modulation has a therapeutic effect and second whether it is able to bind to a small drug-like molecule (Hopkins & Groom, 2002).”
BackgroundIdentifying essential genes in bacterial metabolic networks with machine learning methods
Plaimas, K., Eils, R., & König, R. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-56 · Cited by 135
“The metabolism of a cell is substantial for maintaining life and growth, and hence metabolic enzymes have been successfully targeted by antibiotics inhibiting essential processes in bacterial genomes [1].”
BackgroundVilloutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C., Lagorce, D., Sperandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 116
Chung, S., Funakoshi, T., & Civelli, O. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707606 · Cited by 115
“G protein-coupled receptors are one of the most important drug targets for the pharmaceutical industry as evidenced by the fact that approximately 30% of all marketed drugs act on them (Hopkins and Groom, 2002).”
BackgroundExtrasensory perception: Odorant and taste receptors beyond the nose and mouth
Foster, S. R., Roura, E., & Thomas, W. G. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.004 · Cited by 130
“Not surprisingly, mutations and modifications of GPCRs, G proteins and their regulatory partners are linked to dysfunction and disease (Drews, 2000; Hopkins & Groom, 2002; Wettschureck & Offermanns, 2005; Overington et al., 2006), and the importance of these receptors is reflected in the fact that…”
BackgroundAgoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04385-6 · Cited by 129
Aromatase inhibitors: Role in postmenopausal breast cancer
Kharb, R., Haider, K., Neha, K., & Yar, M. S. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000081 · Cited by 129
Identifying druggable disease-modifying gene products
Dixon, S. J., & Stockwell, B. R. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.08.003 · Cited by 120
“For example, in early surveys, the disease-associated E3 ubiquitin ligase Mdm2, which is amplified in many cancers, was thought to be undruggable [8].”
BackgroundPrediction of potential drug targets based on simple sequence properties
Li, Q., & Lai, L. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-353 · Cited by 115
“Many groups have attempted to develop experimental and computational tools to find new potential drug targets[5,6,11-16].”
The role of fragment-based and computational methods in polypharmacology
Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 128
“Moreover, just a small number of mapped nodes have represented actual drug targets [63], making the earliest implementations extremely prone to provide false positives.”
BackgroundLin, J., Chen, H., Li, S., Liu, Y., Li, X., & Yu, B. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2019.07.005 · Cited by 116
Converting peptides into drugs targeting intracellular protein–protein interactions
Philippe, G. J.-B., Craik, D. J., & Henriques, S. T. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.022 · Cited by 121
Allosteric Modulation of Muscarinic Acetylcholine Receptors
Gregory, K. J., Sexton, P. M., & Christopoulos, A. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695946 · Cited by 115
“However, current CNS-based GPCR drug discovery has a higher than average attrition rate with respect to translating fundamental research to the clinic [41]; this is likely due to two reasons, namely, an insufficient mechanistic understanding of the complexities of CNS GPCR-mediated signaling and a lack of selective ph…”
BackgroundActivation of α‐secretase cleavage
Postina, R. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07459.x · Cited by 109
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
“RNAi can, in principle, be applied to reversibly silence any target gene [reviewed in (8, 9)], thereby increasing the druggable landscape from 10% to virtually 100% of the genome (10, 11).”
BackgroundRediger, A., Piechowski, C. L., Yi, C.-X., Tarnow, P., Strotmann, R., Grüters, A., Krude, H., Schöneberg, T., Tschöp, M. H., Kleinau, G., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.287607 · Cited by 111
Saidi, A., Javerzat, S., Bellahcène, A., Vos, J. D., Bello, L., Castronovo, V., Deprez, M., Loiseau, H., Bikfalvi, A., & Hagedorn, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23313 · Cited by 120
Leveraging base-pair mammalian constraint to understand genetic variation and human disease
Sullivan, P. F., Meadows, J. R. S., Gazal, S., Phan, B. N., Li, X., Genereux, D. P., Dong, M. X., Bianchi, M., Andrews, G., Sakthikumar, S., et al. (2023) · Science · doi:10.1126/science.abn2937 · Cited by 120
G Protein-Coupled Receptors (GPCRs) in Alzheimer’s Disease: A Focus on BACE1 Related GPCRs
Zhao, J., Deng, Y., Jiang, Z., & Qing, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00058 · Cited by 107
“It has been estimated that more than half of all modern drugs are targeted at these receptors (Hopkins and Groom, 2002).”
BackgroundSoluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Protein kinase CK2 as a druggable target
Sarno, S., & Pinna, L. A. (2008) · Molecular BioSystems · doi:10.1039/b805534c · Cited by 113
Pucadyil, T. J., & Chattopadhyay, A. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.01.002 · Cited by 112
“As a consequence, GPCRs represent major targets for the development of novel drug candidates in all clinical areas [10].”
BackgroundLamichhane, R., Liu, J. J., Pljevaljčić, G., White, K. L., der Schans, E. J. C. V., Katritch, V., Stevens, R. C., Wüthrich, K., & Millar, D. P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519626112 · Cited by 111
“G protein-coupled receptors (GPCRs) mediate a multitude of physiological functions and are the targets for a myriad of drugs (1), many of which elicit different functional outcomes through the same receptor (2).”
BackgroundLigand and Decoy Sets for Docking to G Protein-Coupled Receptors
Gatica, E. A., & Cavasotto, C. N. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200412p · Cited by 105
Kozakov, D., Hall, D. R., Napoleon, R. L., Yueh, C., Whitty, A., & Vajda, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00586 · Cited by 115
Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?
Scheele, C., Nielsen, A. R., Walden, T. B., Sewell, D. A., Fischer, C. P., Brogan, R. J., Petrovic, N., Larsson, O., Tesch, P. A., Wennmalm, K., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8520com · Cited by 110
Virtual screening of GPCRs: An in silico chemogenomics approach
Jacob, L., Hoffmann, B., Stoven, V., & Vert, J. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-363 · Cited by 116
Xie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 117
Blonder, J., Chan, K. C., Issaq, H. J., & Veenstra, T. D. (2006) · Nature Protocols · doi:10.1038/nprot.2006.359 · Cited by 110
“It has been estimated that 25% of all open reading frames from sequenced mammalian genomes encode membrane proteins, whereas 65% of all contemporary pharmaceuticals target membrane protein”
BackgroundDrug delivery by red blood cells
Biagiotti, S., Paoletti, M. F., Fraternale, A., Rossi, L., & Magnani, M. (2011) · IUBMB Life · doi:10.1002/iub.478 · Cited by 109
“be about 3,000 representing 10-14% of human product genes (28), thus the challenge is not in the discovery of new leads but in the correct selection of the most useful drug-binding proteins.”
BackgroundPrediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates
Jónsdóttir, S. Ó., Jørgensen, F. S., & Brunak, S. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti314 · Cited by 124
“Several authors have recently published reviews on the use of bio-and chemoinformatics methods in drug discovery processes (Stahura and Bajorath, 2002; Hopkins and Groom, 2002; Golden, 2003).”
BackgroundDissecting complex disease: the quest for the Philosopher's Stone?
Buchanan, A. V., Weiss, K. M., & Fullerton, S. M. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl001 · Cited by 118
Vuckovic, D., Dagley, L. F., Purcell, A. W., & Emili, A. (2013) · PROTEOMICS · doi:10.1002/pmic.201200340 · Cited by 126
“In fact, membrane proteins (MPs) account for nearly 70% of all existing drug targets, with 25% of these belonging to G-protein coupled receptors (GPCRs) [1].”
BackgroundEmerging therapeutic targets for treatment of leishmaniasis
Sundar, S., & Singh, B. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1472241 · Cited by 120
Delivering on the promise of protein degraders
O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 114
G protein inhibition of Ca V 2 calcium channels
Currie, K. (2010) · Channels · doi:10.4161/chan.4.6.12871 · Cited by 110
Characterization of the Drugged Human Genome
Lauss, M., Kriegner, A., Vierlinger, K., & Noehammer, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1063 · Cited by 118
“Despite technological advances, the number of drug targets is growing at a slow and linear pace, with approximately five new human or pathogen drugged targets per year [4,5].”
BackgroundResultInfluentialLaufer, S., Domeyer, D. M., Scior, T., Albrecht, W., & Hauser, D. R. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0408767 · Cited by 108
GPCR stabilization using the bicelle-like architecture of mixed sterol-detergent micelles
Thompson, A. A., Liu, J. J., Chun, E., Wacker, D., Wu, H., Cherezov, V., & Stevens, R. C. (2011) · Methods · doi:10.1016/j.ymeth.2011.10.011 · Cited by 99
“G protein-coupled receptors (GPCRs) represent the largest class of human membrane proteins involved in signal transduction (80%) [6], and remain a largely untapped reservoir of pharmaceutical targets as ~40% of all marketed drugs target only a small fraction of the 800+ members in this protein family [7, 8].”
BackgroundTargeting disordered proteins with small molecules using entropy
Heller, G. T., Sormanni, P., & Vendruscolo, M. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.07.004 · Cited by 107
Moving Beyond Active-Site Detection: MixMD Applied to Allosteric Systems
Ghanakota, P., & Carlson, H. A. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b03515 · Cited by 116
Verschueren, E., Husain, B., Yuen, K. C. Y., Sun, Y. E., Paduchuri, S., Şenbabaoğlu, Y., Lehoux, I. E., Arena, T. A., Wilson, B., Lianoglou, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.007 · Cited by 113
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data
Sharman, J. L., Mpamhanga, C. P., Spedding, M., Germain, P., Staels, B., Dacquet, C., Laudet, V., Harmar, A. J., & NC-IUPHAR (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1062 · Cited by 102
“Members of these protein superfamilies correspond to the biological targets of at least one-third of licensed medicinal drugs (2).”
BackgroundAltamura, F., Rajesh, R., Catta‐Preta, C. M. C., Moretti, N. S., & Cestari, I. D. S. (2020) · Drug Development Research · doi:10.1002/ddr.21664 · Cited by 108
Three ‘E’ challenges for siRNA drug development
Guo, S., Zhang, M., & Huang, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.10.005 · Cited by 108
Chemoproteomic approaches to drug target identification and drug profiling
Bantscheff, M., & Drewes, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.003 · Cited by 124
High-content screening moves to the front of the line
Haney, S. A., LaPan, P., Pan, J., & Zhang, J. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.015 · Cited by 124
Higgs, C., Beuming, T., & Sherman, W. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100008s · Cited by 101
The impact of in silico screening in the discovery of novel and safer drug candidates
Rognan, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.034 · Cited by 120
Computational methods for drug design and discovery: focus on China
Zheng, M., Liu, X., Xu, Y., Li, H., Luo, C., & Jiang, H. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.004 · Cited by 118
“Although this total figure is under debate, it is significantly lower than the number of proteins unveiled by the completion of human and numerous pathogen genomes, of which many can be potentially druggable [3].”
BackgroundLabbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets
Liao, J., Wang, Q., Wu, F., & Huang, Z. (2022) · Molecules · doi:10.3390/molecules27207103 · Cited by 115
“With sequence-based methods, only less than 10% of the human proteome is predicted to be druggable, which suggests a low accuracy [56].”
MethodA two stage click-based library of protein tyrosine phosphatase inhibitors
Xie, J., & Seto, C. T. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.09.036 · Cited by 115
Antifungal Drug Discovery: The Process and Outcomes
Calderone, R., Sun, N., Gay-Andrieu, F., Groutas, W., Weerawarna, P., Prasad, S., Alex, D., & Li, D. (2014) · Future Microbiology · doi:10.2217/fmb.14.32 · Cited by 97
Partridge, F. A., Tearle, A. W., Gravato-Nobre, M. J., Schafer, W. R., & Hodgkin, J. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.02.060 · Cited by 112
“Only a small fraction of genes are ‘druggable’ — pharmaceutically-accessible targets (Hopkins and Groom, 2002; Russ and Lampel, 2005).”
BackgroundFrom Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
Papatzimas, J. W., Gorobets, E., Maity, R., Muniyat, M. I., MacCallum, J. L., Neri, P., Bahlis, N. J., & Derksen, D. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00455 · Cited by 103
Structured and disordered facets of the GPCR fold
Venkatakrishnan, A., Flock, T., Prado, D. E., Oates, M. E., Gough, J., & Babu, M. M. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.08.002 · Cited by 109
“Not surprisingly, GPCRs are among the top protein families that serve as targets for pharmacological intervention [1].”
BackgroundWood, D. J., Lopez‐Fernandez, J. D., Knight, L. E., Al-Khawaldeh, I., Gai, C., Lin, S., Martin, M. P., Miller, D. C., Cano, C., Endicott, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00304 · Cited by 106
Krasowski, A., Muthas, D., Sarkar, A., Schmitt, S., & Brenk, R. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200266d · Cited by 99
Zhu, M., Gao, L., Li, X., Liu, Z., Xu, C., Yan, Y., Walker, E. J., Jiang, W., Su, B., Chen, X., et al. (2009) · Journal of drug targeting · doi:10.1080/10611860903046610 · Cited by 111
“Hopkins and Groom (2002) find that only 10% of the human genome is druggable, and Plewczynski and Rychlewski (2009) recently estimate the size of druggable human genome to be around 20% of whole human proteome by bioinformatics study of sequence and structure similarity.”
BackgroundClinical Success of Drug Targets Prospectively Predicted by In Silico Study
Zhu, F., Li, X. X., Yang, S. Y., & Chen, Y. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.12.002 · Cited by 102
“The impressive capability of the in silico method in prospectively predicting the clinical potential of the drug targets arises from its integrated analysis of multiple druggability properties [2] reported in the literature including sequence similarity to the pre-existing targets [5], binding-site geometric and energ…”
BackgroundLiu, N., Wang, Y., Li, T., & Feng, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105260 · Cited by 111
Current strategies for drug discovery through natural products
Harvey, A. L., Clark, R. L., Mackay, S. P., & Johnston, B. F. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.488263 · Cited by 111
“All of drug discovery to date has used < 500 molecular targets [1] and the ‘druggable’ genome is not much bigger [2,3].”
BackgroundBattistutta, R., Mazzorana, M., Cendron, L., Bortolato, A., Sarno, S., Kazimierczuk, Z., Zanotti, G., Moro, S., & Pinna, L. A. (2007) · ChemBioChem · doi:10.1002/cbic.200700307 · Cited by 102
Frye, S., Crosby, M., Edwards, T., & Juliano, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3462 · Cited by 101
Development and crystallization of a minimal thermostabilised G protein-coupled receptor
Warne, T., Serrano‐Vega, M. J., Tate, C. G., & Schertler, G. F. X. (2009) · Protein Expression and Purification · doi:10.1016/j.pep.2009.01.014 · Cited by 102
“Many therapeutic interventions use drugs that modulate the activities of GPCRs and there is a huge potential for further drug development targeted specifically to this family [5].”
BackgroundPeptidic modulators of protein‐protein interactions: Progress and challenges in computational design
Rubinstein, M., & Niv, M. Y. (2009) · Biopolymers · doi:10.1002/bip.21164 · Cited by 101
New frontiers in proteomics research: A perspective
Dhingra, V., Gupta, M., Andacht, T. M., & Fu, Z. F. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.04.010 · Cited by 119
267 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic Variation
Dopazo, J., Amadoz, A., Bleda, M., García‐Alonso, L., Alemán, A., Garcia‐García, F., Rodríguez, J. A., Daub, J. T., Muntané, G., Rueda, A., et al. (2016) · Molecular Biology and Evolution · doi:10.1093/molbev/msw005 · Cited by 111
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 105
Khoury, A., Deo, K. M., & Aldrich-Wright, J. R. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111070 · Cited by 102
MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets
Kimura, M., Kothari, S. P., Gohir, W., Camargo, J. F., & Husain, S. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-23 · Cited by 109
“Although the human genome encodes 25,000 genes, it is estimated that only 600 disease-modifying protein drug targets exist (234), and only some proteins can be targeted or modulated by a drug molecule.”
Background
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.